GovWire

Guidance: Assessment and procurement of coronavirus (COVID-19) tests

Department Of Health

January 11
12:32 2021

Details

This page contains guidance to help developers of COVID-19 tests understand how their tests are assessed for procurement and use in the UK.

Published 3 June 2020
Last updated 11 January 2021 +show all updates
  1. Updated 'National technical validation process for manufacturers of SARS-CoV-2 (COVID-19) tests' to clarify the procurement process and to reflect the number of technologies currently in the TVG pipeline.

  2. Updated the 'National technical validation process for manufacturers of SARS-CoV-2 (COVID-19) tests' document to add a new validated technology, Abbott.

  3. Updated the 'National technical validation process for manufacturers of SARS-CoV-2 (COVID-19) tests' document to delete a validated technology (Latus) and add a new validated technology (Nonacus).

  4. Updated the 'National technical validation process for manufacturers of SARS-CoV-2 (COVID-19) tests' document to update the 'Products in the pipeline' table and add a new validated technology, Latus.

  5. Updated 'National technical validation process for manufacturers of SARS-CoV-2 (COVID-19) tests': added guidance for antibody test manufacturers about registering interest; added that an alternative technical validation route will be required for any non-machine based LFT and home testing kits; and removed Tenders Electronic Daily as a source of further procurement opportunities.

  6. Added Oxford Nanopore: LamPORE: RNA RT-qPCR to validated technology table in 'National technical validation process for manufacturers of SARS-CoV-2 (COVID-19) tests'.

  7. Updated 'National technical validation process for manufacturers of SARS-CoV-2 (COVID-19) tests' to reflect the number of technologies currently in the TVG pipeline.

  8. Updated 'National technical validation process for manufacturers of SARS-CoV-2 (COVID-19) tests' to add a new validated technology (QuantuMDx), edited links under 'Publication of results' and amended title of 'First wave of non-machine based lateral flow technology (LFT) assessment' to 'First wave of lateral flow test and non-machine based LFT assessment'.

  9. In the attachment National technical validation process for manufacturers of SARS-CoV-2 (COVID-19), updated information about technologies in the pipeline, added new information about validations concluded or paused and added new information and reports on validated technology.

  10. In 'National technical validation process for manufacturers of SARS-CoV-2 (COVID-19) tests', updated information about technologies in the pipeline.

  11. Small amendments made to first 2 paragraphs in 'National technical validation process for manu

Related Articles

Comments

  1. We don't have any comments for this article yet. Why not join in and start a discussion.

Write a Comment

Your name:
Your email:
Comments:

Post my comment

Recent Comments

Follow Us on Twitter

Share This


Enjoyed this? Why not share it with others if you've found it useful by using one of the tools below: